Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GRCE with free AI briefings, catalyst countdowns, and dilution alerts.

GRCE · Grace Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$21.3M Cash on Hand
25.5mo Cash Runway
Follow GRCE by email Get an email when GRCE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GRCE, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
GTX-104 Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 · NCT05995405 Active not recruiting
Nimodipine Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 · NCT05995405 Active not recruiting
Clonidine Pregnancy Related Phase 2 · NCT05487196 Completed
Ropivacaine Pregnancy Related Phase 2 · NCT05487196 Completed
GTX-101 Postherpetic Neuralgia Phase 1 · NCT05517486 Unknown
Ketamine (Ketalar) Dose Level 1 Pain, Postoperative Phase 1 · NCT05907213 Completed
Ketamine (Ketalar) Dose Level 2 Pain, Postoperative Phase 1 · NCT05907213 Completed
Ketamine (Ketalar) Dose Level 3 Pain, Postoperative Phase 1 · NCT05907213 Completed
Ketamine (Ketalar) Dose Level 4 Pain, Postoperative Phase 1 · NCT05907213 Completed
Oxycodone Cesarean Section Complications N/A · NCT05280743 Completed

Also used in these trials (approved or third-party drugs, not GRCE's own candidates): Tirzepatide, Dexmedetomidine, Fentanyl, Bupivacaine Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GRCE holds $21.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 25.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRCE files for a raise →

👥 Who Owns GRCE

Insiders 25.9% Other 5%+ holders 8.2% Institutions (47 holders) 33.1% Public and other holders 32.8%
HolderTypeShares% of sharesAs of
Opaleye Management Inc.
10% owner
Insider 3,054,853 14.52% 2026-11-03
ADAR1 Capital Management, LLC
10% owner
Insider 2,281,877 10.85% 2026-09-30
ADAR1 Capital Management GP, LLC 5%+ holder (13G) 1,717,426 8.16% 2026-03-31
Nantahala Capital Management, LLC Institution (13G, 5%+) 1,654,393 7.86% 2026-09-30
Prashant Kohli
Chief Executive Officer, Director · +621,330 options
Insider 121,357 0.58% 2026-09-09

Share count 21,035,930 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-04-23 GTx-104 NDA -2.7% -45.5% -51.3%
2025-08-22 — NDA -1.5% -1.5% -9.4%

Browse all historical PDUFA outcomes →

Get the full GRCE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRCE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.